Aadi Bioscience (NASDAQ:AADI) Releases Quarterly Earnings Results

Aadi Bioscience (NASDAQ:AADI) announced its quarterly earnings results on Tuesday. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.37), Zacks reports. Aadi Bioscience had a negative net margin of 246.06% and a negative return on equity of 71.87%. The business had revenue of $7.24 million during the quarter, compared to analysts’ expectations of $7.45 million.

Aadi Bioscience Stock Down 2.4 %

Shares of NASDAQ:AADI opened at $2.05 on Wednesday. The company has a market cap of $50.63 million, a PE ratio of -0.90 and a beta of 0.68. The company’s 50-day moving average price is $2.70 and its 200 day moving average price is $2.40. Aadi Bioscience has a fifty-two week low of $1.21 and a fifty-two week high of $3.81.

About Aadi Bioscience

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.